Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resveratrol for Glycemic Variability in T2DM
NCT02549924Phase 2Terminated
- Sponsor
- Universidad de Guadalajara
- Start
- Sep 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Resveratrol with Placebo (2 arms). Primary endpoints: Area under the curve for glucose at 56 days and Mean amplitude of glucose excursions at 56 days. Started Sep 2016; status: terminated.
02
Drugs
resveratrol
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02549924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549924.